304 related articles for article (PubMed ID: 29570615)
1. Neuroimmune Tau Mechanisms: Their Role in the Progression of Neuronal Degeneration.
Cortés N; Andrade V; Guzmán-Martínez L; Estrella M; Maccioni RB
Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29570615
[TBL] [Abstract][Full Text] [Related]
2. Tau alteration and neuronal degeneration in tauopathies: mechanisms and models.
Brandt R; Hundelt M; Shahani N
Biochim Biophys Acta; 2005 Jan; 1739(2-3):331-54. PubMed ID: 15615650
[TBL] [Abstract][Full Text] [Related]
3. Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: Examples of amyloidopathies, tauopathies and synucleinopathies.
Bourdenx M; Koulakiotis NS; Sanoudou D; Bezard E; Dehay B; Tsarbopoulos A
Prog Neurobiol; 2017 Aug; 155():171-193. PubMed ID: 26209472
[TBL] [Abstract][Full Text] [Related]
4. [Neuropathology of tauopathy].
Yoshida M
Brain Nerve; 2013 Dec; 65(12):1445-58. PubMed ID: 24323931
[TBL] [Abstract][Full Text] [Related]
5. Tau pathology in Alzheimer disease and other tauopathies.
Iqbal K; Alonso Adel C; Chen S; Chohan MO; El-Akkad E; Gong CX; Khatoon S; Li B; Liu F; Rahman A; Tanimukai H; Grundke-Iqbal I
Biochim Biophys Acta; 2005 Jan; 1739(2-3):198-210. PubMed ID: 15615638
[TBL] [Abstract][Full Text] [Related]
6. Systemic and network functions of the microtubule-associated protein tau: Implications for tau-based therapies.
Bakota L; Ussif A; Jeserich G; Brandt R
Mol Cell Neurosci; 2017 Oct; 84():132-141. PubMed ID: 28318914
[TBL] [Abstract][Full Text] [Related]
7. [Neuropathology of tauopathies and synucleinopathies, and neuroanatomy of sleep disorders: meeting the challenge].
Hauw JJ; Hausser-Hauw C; Duyckaerts C
Rev Neurol (Paris); 2003 Nov; 159(11 Suppl):6S59-70. PubMed ID: 14646802
[TBL] [Abstract][Full Text] [Related]
8. Identification of key amino acids responsible for the distinct aggregation properties of microtubule-associated protein 2 and tau.
Xie C; Soeda Y; Shinzaki Y; In Y; Tomoo K; Ihara Y; Miyasaka T
J Neurochem; 2015 Oct; 135(1):19-26. PubMed ID: 26134402
[TBL] [Abstract][Full Text] [Related]
9. Tauopathies and tau oligomers.
Takashima A
J Alzheimers Dis; 2013; 37(3):565-8. PubMed ID: 23948895
[TBL] [Abstract][Full Text] [Related]
10. Differential induction and spread of tau pathology in young PS19 tau transgenic mice following intracerebral injections of pathological tau from Alzheimer's disease or corticobasal degeneration brains.
Boluda S; Iba M; Zhang B; Raible KM; Lee VM; Trojanowski JQ
Acta Neuropathol; 2015 Feb; 129(2):221-37. PubMed ID: 25534024
[TBL] [Abstract][Full Text] [Related]
11. Threonine
Moszczynski AJ; Yang W; Hammond R; Ang LC; Strong MJ
Acta Neuropathol Commun; 2017 Jan; 5(1):6. PubMed ID: 28077166
[TBL] [Abstract][Full Text] [Related]
12. Apolipoprotein E epsilon 4 is a determinant for Alzheimer-type pathologic features in tauopathies, synucleinopathies, and frontotemporal degeneration.
Josephs KA; Tsuboi Y; Cookson N; Watt H; Dickson DW
Arch Neurol; 2004 Oct; 61(10):1579-84. PubMed ID: 15477512
[TBL] [Abstract][Full Text] [Related]
13. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders.
Ballatore C; Lee VM; Trojanowski JQ
Nat Rev Neurosci; 2007 Sep; 8(9):663-72. PubMed ID: 17684513
[TBL] [Abstract][Full Text] [Related]
14. Cellular and molecular modifier pathways in tauopathies: the big picture from screening invertebrate models.
Hannan SB; Dräger NM; Rasse TM; Voigt A; Jahn TR
J Neurochem; 2016 Apr; 137(1):12-25. PubMed ID: 26756400
[TBL] [Abstract][Full Text] [Related]
15. Rifampicin is a candidate preventive medicine against amyloid-β and tau oligomers.
Umeda T; Ono K; Sakai A; Yamashita M; Mizuguchi M; Klein WL; Yamada M; Mori H; Tomiyama T
Brain; 2016 May; 139(Pt 5):1568-86. PubMed ID: 27020329
[TBL] [Abstract][Full Text] [Related]
16. Tau and neuroinflammation: What impact for Alzheimer's Disease and Tauopathies?
Laurent C; Buée L; Blum D
Biomed J; 2018 Feb; 41(1):21-33. PubMed ID: 29673549
[TBL] [Abstract][Full Text] [Related]
17. Nitration of tau protein is linked to neurodegeneration in tauopathies.
Horiguchi T; Uryu K; Giasson BI; Ischiropoulos H; LightFoot R; Bellmann C; Richter-Landsberg C; Lee VM; Trojanowski JQ
Am J Pathol; 2003 Sep; 163(3):1021-31. PubMed ID: 12937143
[TBL] [Abstract][Full Text] [Related]
18. Interface between tauopathies and synucleinopathies: a tale of two proteins.
Galpern WR; Lang AE
Ann Neurol; 2006 Mar; 59(3):449-58. PubMed ID: 16489609
[TBL] [Abstract][Full Text] [Related]
19. Increased pro-nerve growth factor and decreased brain-derived neurotrophic factor in non-Alzheimer's disease tauopathies.
Belrose JC; Masoudi R; Michalski B; Fahnestock M
Neurobiol Aging; 2014 Apr; 35(4):926-33. PubMed ID: 24112788
[TBL] [Abstract][Full Text] [Related]
20. Intersection of pathological tau and microglia at the synapse.
Vogels T; Murgoci AN; Hromádka T
Acta Neuropathol Commun; 2019 Jul; 7(1):109. PubMed ID: 31277708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
